Overactive bladder or non-neurogenic overactive bladder is a syndrome characterized by urinary urgency, frequency, nocturia and urgency incontinence.
It is not a disease but a symptom complex that generally is not a life-threatening condition. It is also known as bladder spasms.
Urgency is the complaint of sudden, compelling desire to pass urine that is difficult to deny. It is considered a hallmark symptom of overactive bladder.
Frequency is usually micturition of >7 episodes during waking hours.
Nocturia is the interruption of sleep one or more times because of the need to void.
Urgency incontinence is the involuntary leakage of urine associated with a sudden compelling desire to void.
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.
Selective bladder denervation provides a minimally invasive treatment option for female patients with refractory overactive bladder (OAB), with data from two prospective feasibility studies showing that the intervention improves symptoms over 6 months of follow-up.
A 12-month treatment course with the combination of mirabegron plus solifenacin is safe and effective in patients with overactive bladder (OAB), reducing the number of incontinence episodes and micturition without unexpected toxicities, according to the results of the phase III SYNERGY II study.
There appears to be a substantial percentage of overactive bladder (OAB) patients who have sleep disturbance and fatigue, which are in turn associated with more severe urinary incontinence (UI)/OAB symptoms, worse health-related quality of life and poorer psychosocial health, a study has found.
Older patients with overactive bladder (OAB) appear to have increased frailty compared with individuals seeking care for other nononcologic urologic diagnosis, with frailty being a significant predictor of OAB, a study has found.
In patients with nocturnal urgency secondary to overactive bladder (OAB) and low nocturnal bladder capacity, a mismatch between nocturnal urine production and bladder capacity may predict response to treatment with fesoterodine, according to a study. Symptom improvement appears to be mediated by increases in typical rather than maximum nocturnal voided volumes and be associated with improved quality of life.
Large post-void residual (PVR) volume following onabotulinumtoxin A injection in patients with overactive bladder syndrome (OAB) appear to be associated with low voiding efficiency and low 3-day daytime frequency episodes, a new study reports.
The implant of a tibial nerve stimulator device for overactive bladder (OAB) appears to yield significant improvements in symptoms and quality of life (QoL) without inducing walking disturbances or pain at the implant site, according to a study.
Urinary nerve growth factor/creatinine levels, aside from being a potential biomarker for paediatric overactive bladder (OAB), may also predict therapeutic efficacy in children with OAB, a study suggests.
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
Final overall survival (OS) results from the double-blind phase III FLAURA study reinforce osimertinib as the standard frontline treatment for epidermal growth factor receptor-mutated (EGFRm) non–small cell lung cancer (NSCLC), say leading oncologists at ESMO 2019.
Babies born to mothers exposed to high levels of bisphenol A during pregnancy are at a greater risk of wheezing and poor lung function, according to a new study presented at the recently concluded International Congress of the European Respiratory Society (ERS 2019).